Rheumatology Advance Access published online on January 31, 2006
Rheumatology, doi:10.1093/rheumatology/kel019
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Research Laboratory and Rheumatology Unit, Hospital Clinico Universitario de Santiago de Compostela, Spain
* To whom correspondence should be addressed. Objectives. To investigate the association of a non-synonymous single-nucleotide polymorphism (SNP) in DNASEI with susceptibility to systemic lupus erythematosus (SLE) and the production of autoantibodies to nuclear antigens. Methods. The Gln244Arg (rs1053874) SNP was studied in 276 SLE patients and in 368 healthy controls of Spanish ancestry. Its relationship with SLE susceptibility, serum DNase I activity, anti-ribonucleoprotein (RNP), anti-double-stranded DNA (dsDNA), anti-nucleosome and anti-single-stranded DNA (ssDNA) antibodies was determined. Results. An association of the Gln244Arg SNP with SLE susceptibility that followed a recessive genetic model (P=0.002) was found. The GG genotype was more common in SLE patients (59.8%) than in controls (47.3%). However, the Gln244Arg genotype did not correlate with DNase I activity in sera from SLE patients or from controls. In addition, the Gln244Arg SNP did not influence autoantibody titres significantly. Conclusion. The association of the Gln244Arg SNP with SLE susceptibility indicates that common polymorphisms in DNASEI play a role in the genetics of SLE. However, the lack of effect of the Gln244Arg SNP on serum DNase I activity calls into question the direct involvement of this specific SNP.
Received September 5, 2005
Accepted December 16, 2005
Original Article
Association of a non-synonymous single-nucleotide polymorphism of DNASEI with SLE susceptibility
A. Bodaño 1,
A. González 1,
I. Ferreiros-Vidal 1,
E. Balada 2,
J. Ordi 2,
P. Carreira 3,
J. J. Gómez-Reino 4,
and
C. Conde 1 *
2 Internal Medicine, Research Laboratory in Autoimmune Diseases, Hospital Vall d'Hebron, Barcelona
3 Rheumatology Unit, Hospital 12 de Octubre, Madrid, Spain
4 Research Laboratory and Rheumatology Unit, Hospital Clinico Universitario de Santiago de Compostela, Spain; Department of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
C. Conde, E-mail: Carmen.Conde.Muro{at}sergas.es
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
E. Tinazzi, A. Puccetti, R. Gerli, A. Rigo, P. Migliorini, S. Simeoni, R. Beri, M. Dolcino, N. Martinelli, R. Corrocher, et al. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment Int. Immunol., March 1, 2009; 21(3): 237 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kim, N. W. Hur, H. D. Shin, B. L. Park, H. S. Cheong, and S.-C. Bae Associations of DNase IV polymorphisms with autoantibodies in patients with systemic lupus erythematosus Rheumatology, July 1, 2008; 47(7): 996 - 999. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bodano, A. Gonzalez, E. Balada, J. Ordi, P. Carreira, J. J Gomez-Reino, and C. Conde Study of DNASE I gene polymorphisms in systemic lupus erythematosus susceptibility Ann Rheum Dis, April 1, 2007; 66(4): 560 - 561. [Full Text] [PDF] |
||||


